Beta Drugs
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Beta Drugs is strategically enhancing its competitive position by focusing on high-value oncology, IVF, and dermatology sectors, supported by a robust backward integration into API manufacturing. Management's commitment to innovative drug delivery systems and aggressive R&D investments underpins Vista's forecast of accelerating revenue growth and improving margins. The company's proactive approach to expanding its portfolio through acquisitions and partnerships positions it well to capture market share in high-growth areas. Despite challenges such as geopolitical volatility and regulatory compliance, the outlook remains optimistic, with management anticipating significant growth in FY27 driven by new product registrations. Vista's financial outlook reflects this optimism, projecting a 51.5% expected upside with a 12-month target price of approximately 3423. The favorable industry dynamics, including improving pricing power and resilient demand in chronic therapies, further support this outlook. However, rising input costs and increased competition in the biosimilars space present notable headwinds. Over the next 12-24 months, key opportunities include successful product launches and market expansion, while watchpoints include regulatory challenges and supply chain stability
Why We Like This Stock
- Management's focus on high-value, complex chemistry products and innovative drug delivery systems is expected to drive revenue growth
- Backward integration into API manufacturing enhances supply chain security and margin expansion potential
- Strategic acquisitions and partnerships are likely to broaden market reach and capitalize on growing healthcare spending
Things To Watch Out For
- Geopolitical volatility and regulatory compliance challenges may impact operational execution and market access
- Rising input costs could pressure profit margins despite improving pricing power
- Increased competition in the biosimilars market may affect profitability and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 296 | 362 | 385 | 505 | 613 |
| Profit Before Tax (Cr.) | 49 | 62 | 54 | 80 | 94 |
| PBT Margin | 16.6% | 17.0% | 14.0% | 15.9% | 15.4% |
| Net Profit (Cr.) | 36 | 45 | 41 | 61 | 72 |
| Earnings Per Share | 32.3 | 40.2 | 36.9 | 54.9 | 64.7 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.